ProPhase Net Income From Continuing Ops from 2010 to 2026

PRPH Stock  USD 0.14  0.01  3.33%   
ProPhase Labs' Net Loss is decreasing with slightly volatile movements from year to year. Net Loss is estimated to finish at about -42.3 M this year. For the period between 2010 and 2026, ProPhase Labs, Net Loss quarterly trend regression had mean deviation of  13,081,307 and range of 68 M. View All Fundamentals
 
Net Loss  
First Reported
2000-03-31
Previous Quarter
-4.5 M
Current Value
-6.8 M
Quarterly Volatility
M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check ProPhase Labs financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ProPhase Labs' main balance sheet or income statement drivers, such as Interest Expense of 4 M, Selling General Administrative of 32.4 M or Total Revenue of 7.4 M, as well as many indicators such as Price To Sales Ratio of 2.33, Dividend Yield of 0.13 or PTB Ratio of 2.15. ProPhase financial statements analysis is a perfect complement when working with ProPhase Labs Valuation or Volatility modules.
  
Build AI portfolio with ProPhase Stock
Check out the analysis of ProPhase Labs Correlation against competitors.
For more detail on how to invest in ProPhase Stock please use our How to Invest in ProPhase Labs guide.
The Net Income From Continuing Ops trend for ProPhase Labs offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether ProPhase Labs is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.

Latest ProPhase Labs' Net Income From Continuing Ops Growth Pattern

Below is the plot of the Net Income From Continuing Ops of ProPhase Labs over the last few years. It is ProPhase Labs' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ProPhase Labs' overall financial position and show how it may be relating to other accounts over time.
Net Income From Continuing Ops10 Years Trend
Slightly volatile
   Net Income From Continuing Ops   
       Timeline  

ProPhase Net Income From Continuing Ops Regression Statistics

Arithmetic Mean(8,931,316)
Geometric Mean4,997,667
Coefficient Of Variation(207.35)
Mean Deviation13,081,307
Median(2,710,000)
Standard Deviation18,519,384
Sample Variance343T
Range68M
R-Value(0.55)
Mean Square Error255.9T
R-Squared0.30
Significance0.02
Slope(2,010,013)
Total Sum of Squares5487.5T

ProPhase Net Income From Continuing Ops History

2026-42.3 M
2025-44.6 M
2024-49.5 M
2023-10.5 M
202218.5 M
20216.3 M
2020-2.3 M

About ProPhase Labs Financial Statements

Investors use fundamental indicators, such as ProPhase Labs' Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Although ProPhase Labs' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Net Loss-44.6 M-42.3 M

Currently Active Assets on Macroaxis

When determining whether ProPhase Labs offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ProPhase Labs' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Prophase Labs Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Prophase Labs Stock:
Check out the analysis of ProPhase Labs Correlation against competitors.
For more detail on how to invest in ProPhase Stock please use our How to Invest in ProPhase Labs guide.
You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is there potential for Pharmaceuticals market expansion? Will ProPhase introduce new products? Factors like these will boost the valuation of ProPhase Labs. Anticipated expansion of ProPhase directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about ProPhase Labs listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.95)
Earnings Share
(19.50)
Revenue Per Share
1.402
Quarterly Revenue Growth
(0.38)
Return On Assets
(0.23)
The market value of ProPhase Labs is measured differently than its book value, which is the value of ProPhase that is recorded on the company's balance sheet. Investors also form their own opinion of ProPhase Labs' value that differs from its market value or its book value, called intrinsic value, which is ProPhase Labs' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because ProPhase Labs' market value can be influenced by many factors that don't directly affect ProPhase Labs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between ProPhase Labs' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding ProPhase Labs should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, ProPhase Labs' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.